This begs the question, just how beneficial might a fourth booster infusion be? If Dendreon is going to negotiate with the FDA to change the 9902B statistical plan to allow an earlier interim analysis, they should negotiate to allow a booster infusion for all Provenge patients still alive after 6 months.
A change in the clinical protocol (i.e. patients getting an additional shot) is not possible after the first patient is enrolled.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.